Limits...
A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.

Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD - Am. J. Transplant. (2012)

Bottom Line: The ratios of geometric means were 1.02 (90% CI 97-108%, p = 0.486) for AUC(0-12h) and 1.09 (90% CI 101-118%, p = 0.057) for C(max) .Mean (SD) C(0) was 7.3(1.8) ng/mL for generic tacrolimus versus 7.0(2.1) ng/mL for reference tacrolimus based on data from days 14 and 28.Correlations between 12 h trough levels and AUC were r = 0.917 for generic tacrolimus and r = 0.887 for reference drug at day 28.

View Article: PubMed Central - PubMed

Affiliation: Division of Nephrology, Section of Transplantation, University of Cincinnati, Cincinnati, OH, USA. allowarr@ucmail.uc.edu

Show MeSH

Related in: MedlinePlus

Patient disposition
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3472020&req=5

fig02: Patient disposition

Mentions: Seventy-one patients were recruited to the study and comprised the safety and intent-to-treat (ITT) populations. Three patients were excluded from the pharmacokinetic analysis due to protocol deviations: one patient was dispensed only 45 tablets instead of the planned 70, and substituted his own medication when he ran out of study medication; one did not have assessments performed according to protocol; and one was not on a stable twice-daily dose of study drug prior to entry. The pharmacokinetic population thus comprised 68 patients. A total of 65 patients (91.5%) completed the study (Figure 2). Six patients discontinued the study (four in sequence 1 and two in sequence 2), with one patient discontinuing due to adverse events, two due to consent withdrawal and three for protocol deviations. Two of the discontinuing patients were also protocol violators; results from the other four discontinuing patients were included in individual analyses if the relevant data had been recorded prior to study withdrawal.


A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.

Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Bloom RD - Am. J. Transplant. (2012)

Patient disposition
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3472020&req=5

fig02: Patient disposition
Mentions: Seventy-one patients were recruited to the study and comprised the safety and intent-to-treat (ITT) populations. Three patients were excluded from the pharmacokinetic analysis due to protocol deviations: one patient was dispensed only 45 tablets instead of the planned 70, and substituted his own medication when he ran out of study medication; one did not have assessments performed according to protocol; and one was not on a stable twice-daily dose of study drug prior to entry. The pharmacokinetic population thus comprised 68 patients. A total of 65 patients (91.5%) completed the study (Figure 2). Six patients discontinued the study (four in sequence 1 and two in sequence 2), with one patient discontinuing due to adverse events, two due to consent withdrawal and three for protocol deviations. Two of the discontinuing patients were also protocol violators; results from the other four discontinuing patients were included in individual analyses if the relevant data had been recorded prior to study withdrawal.

Bottom Line: The ratios of geometric means were 1.02 (90% CI 97-108%, p = 0.486) for AUC(0-12h) and 1.09 (90% CI 101-118%, p = 0.057) for C(max) .Mean (SD) C(0) was 7.3(1.8) ng/mL for generic tacrolimus versus 7.0(2.1) ng/mL for reference tacrolimus based on data from days 14 and 28.Correlations between 12 h trough levels and AUC were r = 0.917 for generic tacrolimus and r = 0.887 for reference drug at day 28.

View Article: PubMed Central - PubMed

Affiliation: Division of Nephrology, Section of Transplantation, University of Cincinnati, Cincinnati, OH, USA. allowarr@ucmail.uc.edu

Show MeSH
Related in: MedlinePlus